Survodutide
Survodutide (BI 456906)
GLP-1/glucagon dual agonist by Boehringer Ingelheim. NASH and obesity trials.
Typical vial sizes
Sample reconstitution
5 mg vial · 2 mL bac water · 4.2 mg dose
- Draw volume
- 1.680 mL
- Insulin units
- 168 units
- Concentration
- 2.50 mg/mL
- Doses per vial
- 1.2
From the blog
- Survodutide for MASH: The Glucagon/GLP-1 Dual Agonist's Liver Program
Most of the incretin conversation centers on weight and glucose. Survodutide is interesting because its second target — the glucagon receptor — points somewhere else: the liver. This research log walks through what the published data actually show fo
- Pemvidutide: A GLP-1/Glucagon Dual Agonist in Trials for Obesity and MASH
Pemvidutide (developer code ALT-801, from Altimmune) is an investigational, once-weekly injectable peptide being studied for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). It is described by its developer as a *balanced 1:1
Further reading
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.